Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Corgenix Medical Launches New Anti-Phospholipid Assay

Corgenix Medical, a developer and marketer of diagnostic test kits, has reported the availability of its new automation friendly anti-phospholipid assay format.

Corgenix’ new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis.

Automated microplate Elisa processing from Corgenix is available for a wide range of anti-phospholipid antibody screening tests, including anti-Cardiolipin (aCL) antibodies, anti-Phosphatidylserine (aPS) antibodies and anti-Beta2 Glycoprotein I IgG antibodies.

As the company has obtained FDA clearance for its anti-Cardiolipin test, Corgenix maintains its commitment to offer the highest quality tests associated with SLE (lupus) and antiphospholipid syndrome, autoimmune mediated thrombotic diseases. It is estimated that over 3 million individuals in the US and 10 million worldwide have lupus or lupus-like disorders.

Douglass Simpson, CEO and president of Corgenix, said: “Offering both extended and short assay formats allows us to maintain our leadership position in anti-phospholipid antibody detection. Our customers can now compete more effectively with enhanced automated performance.”